Clario announced on March 17 that it has acquired Canadian company NeuroRx. This marks Clario’s second acquisition of the month.
Based in Montreal, Quebec, NeuroRx is an imaging contract research organization (CRO) that works with the pharmaceutical industry to bring new drugs to market. NeuroRx offers a full set of services including protocol development, qualification and supervision of MRI facilities, as well as collection and analysis of standardized image data.
Clario, formerly ERT and Bioclinica, is a CRO specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations. The company is based in Philadelphia, Pennsylvania.
Earlier in March, Clario announced a signed definitive agreement to acquire WCG‘s electronic clinical outcomes assessments business. Together, the two acquisitions are expected to strengthen Clario’s scientific expertise and service delivery capabilities in the neuroscience therapeutic area. Financial terms of the deal were not disclosed.
According to data in the LevinPro HC database, this transaction represents the sixth CRO acquisition of 2025. There were 33 CRO transactions announced in 2024, and 44 announced in 2023.
